Sculpt contains Tirzepatide, a dual GIP and GLP-1 receptor agonist studied in the landmark SURPASS and SURMOUNT clinical trial programmes. By activating both incretin receptors simultaneously, Tirzepatide represents a significant advance in metabolic peptide research. Each box contains 10 vials of lyophilized powder.
Third-party COA available on request. For research purposes only.


Reviews
There are no reviews yet.